Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Dana Delaski

Nurse Practitioner, Family Jackson, MS Nurse Practitioner

NPI 1467753772 CMS profile 11075371

2500 N State St, Jackson, MS 39216

Open in the dashboard

General payments

$158,131

854 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dana Delaski of Jackson, MS is reported in the CMS Open Payments database as having received $158,131 across 854 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,976 175
2024 General $12,552 154
2023 General $40,084 190
2022 General $53,254 163
2021 General $39,265 172

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dana Delaski
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Dana Delaski were reported at $12,976. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Dana Delaski Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $39,265 $124 $35–$379 $132
2022 $53,254 $141 $44–$430 $149
2023 $40,084 $154 $49–$476 $160
2024 $12,552 $165 $51–$504 $164
2025 $12,976 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Incyte Corporation $144,456 357 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $1,862 22 payments
  3. Vertex Pharmaceuticals Incorporated $932 1 payment
  4. Celgene Corporation $766 30 payments
  5. Novartis Pharmaceuticals Corporation $560 33 payments
  6. Genzyme Corporation $550 29 payments
  7. AstraZeneca Pharmaceuticals LP $529 19 payments
  8. BeiGene USA, Inc. $475 12 payments
  9. Alexion Pharmaceuticals, Inc. $458 11 payments
  10. Janssen Biotech, Inc. $427 25 payments
  11. Other $7,115 315 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $90,193 68 payments
  2. Travel and Lodging $46,123 113 payments
  3. Food and Beverage $18,237 665 payments
  4. Consulting Fee $3,399 6 payments
  5. Education $179 2 payments
Products named General payments · program years 2021–2025
  1. JAKAFI $81,404 232 payments
  2. MONJUVI $74,193 152 payments
  3. REBLOZYL $577 24 payments
  4. SARCLISA $506 26 payments
  5. BRUKINSA $493 13 payments
  6. VENCLEXTA $450 18 payments
  7. IMBRUVICA $333 9 payments
  8. TALVEY $322 8 payments
  9. ULTOMIRIS $321 8 payments
  10. KEYTRUDA $294 14 payments
  11. Other $9,023 433 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

827

Median for Nurse Practitioner: 389

Drug cost

$214,834

Median for Nurse Practitioner: $21,885

Branded share of claims

34.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Deferasirox Generic 48 $153,763
Xarelto Rivaroxaban Brand 33 $28,283
Eliquis Apixaban Brand 37 $21,360
Morphine Sulfate Er Morphine Sulfate Brand 53 $1,693
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 98 $1,260
Hydroxyurea Generic 42 $1,253
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 42 $1,179
Gabapentin Generic 50 $760
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 13 $696
Colestipol Hcl Generic 13 $683

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$16,964

Medicare's payments for the services billed

Medicare patients

149

Average age 64

Services billed

318

96 women, 53 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Chronic kidney disease 30%
Diabetes 28%
Ischemic heart disease 23%
Depression 21%
Heart failure 20%
Atrial fibrillation 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 51 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JAKAFI
$9,861 — —
SARCLISA
$158 — —
BRUKINSA
$141 — —
TALVEY
$140 — —
REBLOZYL
$132 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 51 with Patron

Records

854 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record